Japanese denosumab approval furthers Daiichi Sankyo's oncology ambitions
This article was originally published in Scrip
Amgen's RANK ligand inhibitor denosumab has been formally approved in Japan as Ranmark through local licensee Daiichi Sankyo for the indications of bone disorders stemming from bone metastases of solid tumours and bone complications of multiple myeloma.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.